Granted Patent
B2
US 12,365,874 · App. 17/489,607 · Granted Jul 22, 2025
Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
Inventors:
John H. Lee (Culver City, CA); Laurent H. Boissel (Culver City, CA); Hans G. Klingemann (Culver City, CA)
Assignee:
ImmunityBio, Inc.
C12N5/0646A61K40/15A61K40/31A61K40/4204A61K40/4205A61K45/06A61P35/00C07K14/5434C07K14/5443C07K14/55C07K14/70535C07K14/71C07K16/2863C07K16/32A61K2239/31A61K2239/38A61K2239/50C07K2317/24C07K2317/53C07K2317/622C07K2317/732C07K2319/02C07K2319/03C07K2319/30C07K2319/33
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided are genetically modified NK cells expressing a chimeric antigen receptor targeting an EGFR superfamily receptor. The CAR can comprise an intracellular domain of FcεRIγ and further recombinant proteins expressed by the genetically modified NK cells are CD16, autocrine growth stimulating cytokines, and optionally one of IL-12, a TGF-beta trap, or a homing receptor. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient the genetically modified NK cells.
Claims (26)
1. A genetically modified NK cell comprising one or more recombinant nucleic acids encoding and expressing
(i) a membrane bound recombinant chimeric antigen receptor (CAR) that comprises in a single polypeptide chain an extracellular binding domain that specifically binds to an EGFR superfamily receptor, a hinge domain, a transmembrane domain, and a FcεRIγ signaling domain having the polypeptide sequence of SEQ ID NO:1; wherein the extracellular binding domain that specifically binds to an EGFR superfamily receptor is an EGFR scFv having the amino acid sequence of SEQ ID NO: 41 or a HER2/neu scFv having the amino acid sequence of SEQ ID NO:43;
(ii) a recombinant CD16; and
(iii) an autocrine growth stimulating cytokine.
2. The genetically modified NK cell of claim 1 wherein the NK cell is an NK-92 cell and/or wherein the recombinant CD16 is a CD16 158V mutant.
3. The genetically modified NK cell of claim 1 wherein the autocrine growth stimulating cytokine is IL-2 or IL-15, and optionally wherein the autocrine IL-2 or IL-15 further comprises an endoplasmic retention sequence.
4. The genetically modified NK cell of claim 1 wherein the nucleic acid further encodes and the cell expresses one of IL-12, a TGF-beta trap, or a homing receptor.
5. The genetically modified NK cell of claim 4 wherein the TGF-beta trap comprises a single chain dimer of the TGF-beta Receptor II ectodomain, or wherein the TGF-beta trap is a secreted form of a single chain dimer of the TGF-beta Receptor II ectodomain.
6. The genetically modified NK cell of claim 4 wherein the IL-12 is a single chain IL-12 heterodimer.
7. The genetically modified NK cell of claim 4 wherein the homing receptor is selected from the group consisting of CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, CXCR7, CX3CR1, XCR1, CCXCKR, D6, DARC, and a receptor for CXCL14.
8. A genetically modified NK cell, comprising:
a recombinant nucleic acid encoding
(i) a membrane bound recombinant chimeric antigen receptor (CAR) that comprises in a single polypeptide chain an extracellular binding domain that specifically binds to an EGFR superfamily receptor, a hinge domain, a transmembrane domain, and a FcεRIγ signaling domain having the polypeptide sequence of SEQ ID NO:1; wherein the extracellular binding domain that specifically binds to an EGFR superfamily receptor is an EGFR scFv having the amino acid sequence of SEQ ID NO: 41 or a HER2/neu scFv having the amino acid sequence of SEQ ID NO:43;
(ii) a recombinant CD16; and
(iii) an autocrine growth stimulating cytokine.
9. The genetically modified NK cell of claim 8 wherein the recombinant nucleic acid is a polycistronic DNA.
10. The genetically modified NK cell of claim 8 wherein the NK cell is an NK-92 cell, and/or wherein the recombinant CD16 is a CD16 158V mutant.
11. The genetically modified NK cell of claim 8 wherein the autocrine growth stimulating cytokine is IL-2 or IL-15, and optionally wherein the autocrine IL-2 or IL-15 further comprises an endoplasmic retention sequence.
12. The genetically modified NK cell of claim 8 wherein the recombinant nucleic acid further encodes an IL-12, a TGF-beta trap, or a homing receptor.
13. The genetically modified NK cell of claim 12 wherein the TGF-beta trap comprises a secreted form of a single chain dimer of the TGF-beta Receptor II ectodomain, and/or wherein the IL-12 is a single chain IL-12 heterodimer.
14. The genetically modified NK cell of claim 12 wherein the homing receptor is selected from the group consisting of CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, CXCR7, CX3CR1, XCR1, CCXCKR, D6, DARC, and a receptor for CXCL14.
15. A method of treating cancer in a patient in need thereof, comprising
administering to the patient a therapeutically effective amount of the genetically modified NK cell of claim 1 and thereby treating the cancer, wherein the genetically modified NK cell is autologous or allogeneic to the patient.
16. The method of claim 15 further comprising a step of administering at least one additional therapeutic entity selected from the group consisting of a viral cancer vaccine, a bacterial cancer vaccine, a yeast cancer vaccine, N-803, an antibody, a stem cell transplant, and a tumor targeted cytokine.
17. The method of claim 15 , wherein the cancer is a lung cancer, a breast cancer, a thyroid cancer, an esophageal cancer, a gastric cancer, a gastroesophageal cancer, or a head and neck cancer.
18. The method of claim 15 , wherein about 1×10 8 to about 1×10 11 cells per m 2 of body surface area of the patient are administered to the patient.
Assignments (2)
NUNC PRO TUNC ASSIGNMENT
Recorded Feb 14, 2025
From: LEE, JOHN H.; BOISSEL, LAURENT H.; KLINGEMANN, HANS G.
To: IMMUNITYBIO, INC.
Reel/Frame 070220/0405 →
SECURITY INTEREST
Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
Continuity (2)
References Cited (214)
US 6034072A
· Ralston et al.
· 2000
[cited by applicant]
US 7098008B2
· Park et al.
· 2006
[cited by applicant]
US 7618817B2
· Campbell
· 2009
[cited by applicant]
US 8034332B2
· Klingemann
· 2011
[cited by applicant]
US 8067227B2
· Wahler
· 2011
[cited by examiner]
US 8313943B2
· Campbell
· 2012
[cited by applicant]
US 8987417B2
· Zwaagstra et al.
· 2015
[cited by applicant]
US 9061059B2
· Chakraborty et al.
· 2015
[cited by applicant]
US 9150636B2
· Campbell
· 2015
[cited by applicant]
US 9181322B2
· Campbell
· 2015
[cited by applicant]
US 9266938B2
· Ast et al.
· 2016
[cited by applicant]
US 20020068044A1
· Klingemann
· 2002
[cited by applicant]
US 20030105292A1
· Liaw et al.
· 2003
[cited by applicant]
US 20030167531A1
· Russell et al.
· 2003
[cited by applicant]
US 20040052770A1
· Klingemann
· 2004
[cited by applicant]
US 20080247990A1
· Campbell
· 2008
[cited by applicant]
US 20130040386A1
· Campbell
· 2013
[cited by applicant]
US 20130189268A1
· Du et al.
· 2013
[cited by applicant]
US 20130280285A1
· Schonfeld et al.
· 2013
[cited by applicant]
US 20140099714A1
· Klingemann
· 2014
[cited by applicant]
US 20140242701A1
· Shiku et al.
· 2014
[cited by applicant]
US 20140255363A1
· Metelitsa et al.
· 2014
[cited by applicant]
US 20140274909A1
· Orentas et al.
· 2014
[cited by applicant]
US 20140322183A1
· Milone et al.
· 2014
[cited by applicant]
US 20170260268A1
· Beatty et al.
· 2017
[cited by applicant]
US 20180057796A1
· Woodruff et al.
· 2018
[cited by applicant]
US 20180134766A1
· Larson et al.
· 2018
[cited by applicant]
US 20180163176A1
· Lee
· 2018
[cited by applicant]
US 20180193383A1
· Lee et al.
· 2018
[cited by applicant]
US 20180207295A1
· Fotin-Mleczek et al.
· 2018
[cited by applicant]
US 20180258397A1
· Klingemann et al.
· 2018
[cited by applicant]
US 20200038441A1
· Klingemann et al.
· 2020
[cited by applicant]
US 20200093863A1
· Klingemann et al.
· 2020
[cited by applicant]
US 20210169931A1
· Boissel et al.
· 2021
[cited by applicant]
US 20240252540A1
· Lee et al.
· 2024
[cited by applicant]
CA 3060443A1
· 2018
[cited by applicant]
CN 103230600A
· 2013
[cited by applicant]
CN 105331585A
· 2016
[cited by applicant]
CN 107108744A
· 2017
[cited by applicant]
CN 107384870A
· 2017
[cited by applicant]
CN 107580628A
· 2018
[cited by applicant]
CN 107709552A
· 2018
[cited by applicant]
CN 108264567A
· 2018
[cited by applicant]
CN 109575139A
· 2019
[cited by applicant]
CN 109804064A
· 2019
[cited by applicant]
CN 110546168A
· 2019
[cited by applicant]
CN 110564695A
· 2019
[cited by applicant]
JP 2015529457A
· 2015
[cited by applicant]
JP 2018510881A
· 2018
[cited by applicant]
JP 2018509459A
· 2018
[cited by applicant]
JP 2018518974A
· 2018
[cited by applicant]
JP 2021532771A
· 2021
[cited by applicant]
WO 9849268A1
· 1998
[cited by applicant]
WO 9924566A1
· 1999
[cited by applicant]
WO 0020460A1
· 2000
[cited by applicant]
WO 03008583A2
· 2003
[cited by applicant]
WO 03035837A2
· 2003
[cited by applicant]
WO 2003084570A1
· 2003
[cited by applicant]
WO 03101485A1
· 2003
[cited by applicant]
WO 2008157367A1
· 2008
[cited by applicant]
WO 2014022423A2
· 2014
[cited by applicant]
WO 2014039523A1
· 2014
[cited by applicant]
WO 2014099671A1
· 2014
[cited by applicant]
WO 2016048903A1
· 2016
[cited by applicant]
WO 2016160602A2
· 2016
[cited by applicant]
WO 2016168595A1
· 2016
[cited by applicant]
WO 2016160621A2
· 2016
[cited by applicant]
WO 2016176639A1
· 2016
[cited by applicant]
WO 2016201304A1
· 2016
[cited by applicant]
WO 2016210293A1
· 2016
[cited by applicant]
WO 2017040945A1
· 2017
[cited by applicant]
WO 2017112741A1
· 2017
[cited by applicant]
WO 2017123548A1
· 2017
[cited by applicant]
WO 2017214569A1
· 2017
[cited by applicant]
WO 2018053270A1
· 2018
[cited by applicant]
WO 2018064594A2
· 2018
[cited by applicant]
WO 2018068766A1
· 2018
[cited by applicant]
WO 2018076391A1
· 2018
[cited by applicant]
WO 2018104562A1
· 2018
[cited by applicant]
WO 2018161017A1
· 2018
[cited by applicant]
WO 2019062755A1
· 2019
[cited by applicant]
WO 2019089813A1
· 2019
[cited by applicant]
WO 2019152513A1
· 2019
[cited by applicant]
WO 2019226521A1
· 2019
[cited by applicant]
WO 2019226708A1
· 2019
[cited by applicant]
WO 2020010110A1
· 2020
[cited by applicant]
WO 2020028656A1
· 2020
[cited by applicant]
International Preliminary Report on Patentability Chapter II received for PCT Application Serial No. PCT/US2019/044655, dated Jul. 24, 2020, 14 pages.
[cited by applicant]
International Search Report and Written opinion received for PCT Application Serial No. PCT/US2020/015487 dated Oct. 27, 2020, 11 pages.
[cited by applicant]
Final Office Action received for U.S. Appl. No. 16/529,029 dated Nov. 6, 2020, 29 pages.
[cited by applicant]
ATCC Genetically modified natural killer cell line retroviral transduced to express CD-16 (PTA-8836), downloaded Nov. 3, 2020, pp. 1-2.
[cited by applicant]
ATCC Genetically modified natural killer cell lines, downloaded Nov. 3, 2020 pp. 1-5.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/707,807 dated Nov. 10, 2020, 33 pages.
[cited by applicant]
Randolph Gwendalyn J, “Dendritic cell migration to lymph nodes: cytokines, chemokines, and lipid mediators”, Seminars in Immunology, 2001, vol. 13, pp. 267-274.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/708,082 dated Nov. 16, 2020, 39 pages.
[cited by applicant]
Jochems et al., “An NK cell line (haN K) expressing high levels of granzyme and engineered to express the high affinity CD16 allele”, Oncotarget 2016, vol. 7, No. 52, pp. 86359-86373.
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 16/529,029 dated Jan. 13, 2021, 16 pages.
[cited by applicant]
Final Office Action received for U.S. Appl. No. 16/775,111 dated Jan. 11, 2021, 59 pages.
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 16/529,029 dated Feb. 9, 2021, 7 pages.
[cited by applicant]
Final Office Action received for U.S. Appl. No. 16/707,807 dated Mar. 17, 2021, 103 pages.
[cited by applicant]
Ngo et al., “Computational Complexity,Protein Structure Prediction,and the Levinthal Paradox”, The Protein Folding Problem and Tertiary Structure Prediction, 1994, pp. 433-495.
[cited by applicant]
Rudinger J., “Characteristics of the amino acids as components of a peptide hormone sequene”, Peptide Hormones, 1976, 8 pages.
[cited by applicant]
Final Office Action received for U.S. Appl. No. 16/708,082 dated Mar. 16, 2021, 44 pages.
[cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity” Proceedings of National Academy of Sciences, 1982, vol. 79, pp. 1979-1983.
[cited by applicant]
Coleman et al., “Effects of amino acid sequence changes on antibody-antigen interactions”, Research in Immunology, 1994, vol. 145, pp. 33-36.
[cited by applicant]
Almagro et al., “Humanization of antibodies”, Frontiers in Bioscience, 2008, vol. 13, No. 5, pp. 1619-1633.
[cited by applicant]
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) GrowthFactor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single …
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 16/708,082 dated May 21, 2021, 18 pages.
[cited by applicant]
Non Final Office Action received for U.S. Appl. No. 16/775,111 dated Jun. 15, 2021, 34 pages.
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 16/707,807 dated Jul. 16, 2021, 27 pages.
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 16/775,111 dated Sep. 7, 2021, 30 pages.
[cited by applicant]
Notice of Reasons for Refusal received for Japanese Patent Application Serial No. 2021-505238 dated Apr. 1, 2022, 10 pages. (Including English Translation).
[cited by applicant]
Office Action received for Israel Patent Application Serial No. 280511 dated Jun. 1, 2022, 12 pages. (Including English Translation).
[cited by applicant]
International Preliminary Report on Patentability received for PCT Application Serial No. PCT/US2020/015487 dated Aug. 11, 2022, 8 pages.
[cited by applicant]
Examination Report No. 1 received for Australian Patent Application Serial No. 2019314455 dated Apr. 12, 2023, 4 pages.
[cited by applicant]
Office Action received for Israel Patent Application Serial No. 296050 dated Apr. 4, 2023, 11 pages. (Including English Translation).
[cited by applicant]
First Office Action received for Chinese Patent Application Serial No. 201980051071.5 dated Aug. 12, 2023, 19 pages. (Including English Translation).
[cited by applicant]
Notice of Final Rejection received for Korean Patent Application Serial No. 10-2021-7005791 dated Aug. 21, 2023, 7 pages. (Including English Translation).
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 16/775,111 dated Dec. 10, 2021, 6 pages.
[cited by applicant]
Notice of Intent to Grant received for Israel Patent Application Serial No. 280511 dated Aug. 29, 2022, 2 pages. (Including English Translation).
[cited by applicant]
Notice of Reasons for Refusal received for Japanese Patent Application Serial No. 2021-505238 dated Oct. 7, 2022, 4 pages. (Including English Translation).
[cited by applicant]
Office Action received for Canadian Patent Application Serial No. 3,106,324 dated Nov. 15, 2022, 5 pages.
[cited by applicant]
Sahm et al., “Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor”, Springer, Cancer Immunol Immunother, vol. 61…
[cited by applicant]
Decision to Grant a Patent received for Japanese Patent Application Serial No. 2021-505238 dated Feb. 3, 2023, 6 pages. (Including English Translation).
[cited by applicant]
Request for the Submission of an Opinion received for Korean Patent Application Serial No. 10-2021-7005791 dated Feb. 21, 2023, 9 pages. (Including English Translation).
[cited by applicant]
Office Action received for Israel Patent Application Serial No. 280511 dated Jan. 10, 2022, 15 pages. (Including English Translation).
[cited by applicant]
Abate-Daga et al., “CAR models: next -generation CAR modifications for enhanced T-cell function”, Oncolytics, 2016, vol. 3, No. 16014, pp. 1-7.
[cited by applicant]
ATCC N K-92 product , Credible leads to incredible; downloaded Dec. 5, 2019, pp. 1-6.
[cited by applicant]
Konstantinidis et al., “Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells” Experimental Hematology, 2005, vol. 33, pp. 159-164.
[cited by applicant]
International Search Report and Written opinion received for PCT Application Serial No. PCT/US19/44655, dated Dec. 4, 2019, 17 pages.
[cited by applicant]
GenBank MH107787, “Mammalian expression vector pEXPR50, complete sequence”, Apr. 11, 2018, URL: https://www.ncbi.nlm.nih.gov/nuccore/MH107787.1/, 3 pages.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/529,029 dated Dec. 11, 2019, 26 pages.
[cited by applicant]
Swarts et al., “Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy”, Cancer Research, 2012, vol. 72, pp. 2473-2480.
[cited by applicant]
Herberman et al., “Natural Killer Cells: Their Role in Defenses Against Disease”, Science, Oct. 2, 1981, vol. 214, pp. 24-30.
[cited by applicant]
Smith et al., “Comparison of Biosequences”, Advances in applied mathematics 2, 1981, pp. 482-489.
[cited by applicant]
Needleman et al., “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins”, J. Mol. Biol., 1970, vol. 48, pp. 443-453.
[cited by applicant]
Pearson et al., “Improved tools for biological sequence comparison”, Biochemistry, Proc. Natl. Acad. Sci. USA, Apr. 1988, vol. 85, pp. 2444-2448.
[cited by applicant]
Altschul et al., “Gapped Blast and PSI-BLAST: A new generation of protein database search programs”, Nucleic Acids Research, 1997, vol. 25, No. 17, pp. 3389-3402.
[cited by applicant]
Altschul et al., “Basic Local Alignment Tool”, J. Mol. Biol., 1990, vol. 215, pp. 403-410.
[cited by applicant]
Henikoff et al., “Amino acid substitution matrices from protein blocks”, Biochemistry, Proc. Natl. Acad. Sci. USA, Nov. 1992, vol. 89, pp. 10915-10919.
[cited by applicant]
Gong et al., “Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells”, Leukemia, Apr. 1994, vol. 8, No. 4, pp. 652-658.
[cited by applicant]
Maki et al., “Factors Regulating the Cytotoxic Activity of the Human Natural Killer Cell Line, NK-92”, Journal of hematotherapy & Stem Cell Research, 2001, vol. 10, pp. 369-383.
[cited by applicant]
Suck et al., “NK 92: an ‘off the shelf therapeutic’ for adoptive natural killer cell based cancer immunotherapy”, Cancer Immunol Immunotherapy, Nov. 11, 2015, 8 pages.
[cited by applicant]
Klingemann et al., “Purging of malignant cells from blood after short ex vivo incubation with NK-92 cells”, Blood, 1996, vol. 87, No. 11, pp. 4913-4914.
[cited by applicant]
Yan et al., “Antileukemia activity of a natural killer cell line against human leukaemia's”, Clinical Cancer Research, Nov. 1998, vol. 4, pp. 2859-2868.
[cited by applicant]
Swift et al., “Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model”, Haematologica, Cell Therapy and Immunotherapy, …
[cited by applicant]
Tam et al., “Immunotherapy of Malignant Melanoma in a SCID Mouse Model Using the Highly Cytotoxic Natural Killer Cell Line NK-92”, Journal of Hematotherapy, 1999, vol. 8, pp. 281-290.
[cited by applicant]
Zwaagstra et al., “Engineering and Therapeutic Application of Single-Chain Bivalent TGF-β Family Traps”, Molecular Cancer Therapy 2012, vol. 11, No. 7, pp. 1477-1487.
[cited by applicant]
Batzer et al., “Enhanced evolutionary PCR using oligonucleotides with inosine at the 3′-terminus”, Nucleic Acids Research, 1991, vol. 19, No. 18, 1 page.
[cited by applicant]
Ohtsuka et al., “An Alternative Approach to Deoxyoligonucleotides as Hybridization Probes by Insertion of Deoxyinosine at Ambiguous Codon Positions”, The Journal of Biological Chemistry, Mar. 10, 1985, vol. 260, No. 5, …
[cited by applicant]
Rossolini et al., Use of deoxyinosine-containing primers vs Degenerate primers for polymerase chain reaction based on Ambiguous sequence information, Molecular and Cellular Probes, 1994, vol. 8, pp. 91-98.
[cited by applicant]
Yazawa et al., “Current Progress in Suicide gene therapy for cancer”, World J. Surg., 2002, vol. 26, No. 7, pp. 783-789.
[cited by applicant]
Final Office Action received for U.S. Appl. No. 16/529,029 dated Feb. 20, 2020, 21 pages.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/707,807 dated Feb. 14, 2020, 23 pages.
[cited by applicant]
Clark et al., “Inferring nonneutral evolution from human-chimp-mouse orthologous gene trios”, Science, 2003, vol. 302, pp. 1960-1963.
[cited by applicant]
Somanchi et al., “Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7”, Blood, 2012, vol. 119, No. 22, 5164-5172.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/708,082 dated Feb. 18, 2020, 16 pages.
[cited by applicant]
Haynes et al., “Redirecting Mouse CTL Against Colon Carcinoma: Superior Signaling Efficacy of Single-Chain Variable Domain Chimeras Containing TCR-ζ vs FcεRI-γ”, The Journal of Immunology, 2001, vol. 166, No. 1, pp. 182…
[cited by applicant]
Cartellieri et al., “Chimeric antigen receptor-engineered T cells for immunotherapy of cancer”, Journal of Biomedicine and Biotechnology, 2010, vol. 10, pp. 1-13.
[cited by applicant]
Bollino et al., “Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy”, Translational Research, Sep. 2017, vol. 187, 21 pages.
[cited by applicant]
Bruhns et al., “Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses”, Blood, vol. 113, No. 16, pp. 3716-3725.
[cited by applicant]
Garcia-Sanchez et al., “Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologou…
[cited by applicant]
Touati et al., “A suicide gene therapy combining the improvement of cyclophosphamide tumor cytotoxicity and the development of an anti-tumor immune response”, Current Gene Therapy, 2014, vol. 14, pp. 236-246.
[cited by applicant]
Di Stasi et al., “Inducible apoptosis as a safety switch for adoptive cell therapy”, N Engl J Med., Nov. 3, 2011, vol. 365, No. 18, 16 pages.
[cited by applicant]
Morgan Richard A, “Live and Let Die: A New Suicide Gene Therapy Moves to the Clinic”, Molecular therapy, Jan. 2012, vol. 20, No. 1, pp. 11-13.
[cited by applicant]
Wang et al., “Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-betaR II and NKG2D”, Cancer Immunol Immunother, 2017, 12 pages.
[cited by applicant]
Yang et al., “Blocking transforming growth factor-beta signaling pathway augments antitumor effect of adoptive NK-92 cell therapy”, International Immunopharmacology, 2013, vol. 17, pp. 198-204.
[cited by applicant]
Non Final Office Action received for U.S. Appl. No. 16/529,029 dated Jun. 8, 2020, 32 pages.
[cited by applicant]
NK-92® ATCC® CRL-2407™
[cited by applicant]
NK-92® MI ATCC® CRL-2408™
[cited by applicant]
NK-92® ATCC® CRL-2407™ b
[cited by applicant]
Final Office Action received for U.S. Appl. No. 16/707,807 dated Jun. 4, 2020, 29 pages.
[cited by applicant]
Denman et al., “Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells”, Plos One, Jan. 2012, vol. 7, No. 1, e30264, pp. 1-12.
[cited by applicant]
Final Office Action received for U.S. Appl. No. 16/708,082 dated Jun. 5, 2020, 27 pages.
[cited by applicant]
Non Final Office Action received for U.S. Appl. No. 16/775,111 dated Aug. 7, 2020, 39 pages.
[cited by applicant]
Notice of Acceptance received for Australian application No. 2019314455 dated Mar. 21, 2024, 03 pages.
[cited by applicant]
Office Action received for Chinese application No. 201980051071.5 dated Jun. 1, 2024, 21 pages (including English Translation).
[cited by applicant]
Office Action received for Chinese application No. 201980051071.5 dated Aug. 10, 2024, 17 pages (including English Translation).
[cited by applicant]
Kerbauy et al., “Cord Blood NK Cells Engineered to Express a Humanized CD123-Targeted Chimeric Antigen Receptor (CAR) and IL-15 as Off-the-Shelf Therapy for Acute Myeloid Leukemia”, Blood (2017) 130 (Suppl_ 1 ): 4453.
[cited by applicant]
Zhang et al., “Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity”, Frontiers in Immunology, v…
[cited by applicant]
Genßler et, al., “Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival”, Oncoimm…
[cited by applicant]
Isakov N., “Immunoreceptor tyrosine-based activation motif (ITAM), a unique module linking antigen and Fc receptors to their signaling cascades” J Leukoc Biol. Jan. 1997;61(1):6-16.
[cited by applicant]
Schomer et al, “Providing a Homing Receptor for CAR Engineered NK Cells—Improving Cellular Immunotherapy for B-Cell Lymphoma” , Blood, American Society of Hematology, US, vol. 132, Nov. 29, 2018 (Nov. 29, 2018), p. 4547.
[cited by applicant]
Zwaagstra et al, “Engineering and Therapeutic Application of Single-Chain Bivalent TGF-β; Family Traps”, Molecular Cancer Therapeutics, vol. 11, No. 7, Jul. 1, 2012 (Jul. 1, 2012), pp. 1477-1487.
[cited by applicant]
Klingemann, “The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer”, Cytotherapy, vol. 25, No. 5, May 1, 2023 (May 1, 2023), pp. 451-457.
[cited by applicant]
Hou et al., “TGF-b-responsive CAR-T cells promote anti-tumor immune function”, Bioengineering & Translational Medicine 2018;3:75-86.
[cited by applicant]
Extended European Search Report received for EP Application No. 19843481.3 dated Sep. 19, 2022, 16 pages.
[cited by applicant]
Extended European Search Report received for EP Application No. 20916474.8 dated Sep. 11, 2023, 11 pages.
[cited by applicant]
Klingemann et al., “Natural Killer Cells for immunotherapy—Advantages of the NK-92 Cell Line over Blood NK Cells”, Frontiers in Immunology, 2016, vol. 7, Article 91, 7 Pages.
[cited by applicant]
Lind H, et al., “Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances”, J Immunother Cancer 2020;8:e000433:e1426519.
[cited by applicant]
Notice of Reasons for Refusal received for JP Application No. 2023-033995 dated Apr. 12, 2024, 10 pages (including English Translation).
[cited by applicant]
Office Action received for KR Application No. 10-2024-7010547 dated Jun. 14, 2024, 10 pages (including English Translation).
[cited by applicant]
Office Action received for KR Application No. 10-2024-7010547 dated Feb. 1, 2025, 9 pages (including English Translation).
[cited by applicant]
Knudson et al., “M7824, a novel bifunctional anti-PD-L1/TGFb Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine,” Oncoimmunology 2018, vol. 7, No. 5, e1426519 (14 pages).
[cited by applicant]
Partial Search Report received for EP Application No. 19843481.3 dated May 30, 2022, 11 pages.
[cited by applicant]
Yunhan et al., “Clinical application of chimeric antigen receptor-engineered T cells in treatment of solid tumors”, Academic Journal of Second Military Medical University, vol. 37, No. 4, 18 pages (including English Tra…
[cited by applicant]
Office Action received for CA Application No. 3,106,324 dated Dec. 20, 2021, 4 pages.
[cited by applicant]
Office Action received for CN Application No. 202080094731.0 dated Nov. 15, 2024, 29 pages (including English Translation).
[cited by applicant]
Office Action received for CN Application No. 202080094731.0 dated Jun. 13, 2024, 28 pages (including English Translation).
[cited by applicant]
Office Action received for CN Application No. 202080094731.0 dated Feb. 17, 2025, 27 pages (including English Translation).
[cited by applicant]
Jochems et al., “Analyses of functions of an anti-PD-L1/TGFBR2 bispecific fusion protein (M7824)”, Oncotarget, 2017, vol. 8, (No. 43), pp. 75217-75231.
[cited by applicant]
Office Action received for IL Application No. 314189 dated Feb. 6, 2025, 6 pages (including English Translation).
[cited by applicant]